Carbon monoxide enhances calcium transients and glucose-stimulated insulin secretion from pancreatic β-cells by activating Phospholipase C signal pathway in diabetic mice

Biochem Biophys Res Commun. 2021 Dec 10:582:1-7. doi: 10.1016/j.bbrc.2021.10.030. Epub 2021 Oct 16.

Abstract

In early stage of diabetes, insulin secretion from pancreatic β-cells is increased to deal with the elevated blood glucose. Previous studies have reported that islet-produced carbon monoxide (CO) is associated with increased glucose-stimulated insulin secretion from β-cells. However, this compensatory mechanism by which CO may act to enhance β-cell function remain unclear. In this study, we revealed that CO promoted intracellular calcium ([Ca2+]i) elevation and glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells in leptin receptor deficient db/db mice but not in C57 mice. The stimulatory effects of CO on β-cell function in db/db mice was blocked by inhibition of Phospholipase C (PLC) signaling pathway. We further demonstrated that CO triggered [Ca2+]i transients and enhanced GSIS in C57 islets when β-cells overexpressed with PLCγ1 and PLCδ1, but not PLCβ1. On the other hand, reducing PLCγ1 and PLCδ1 expressions in db/db islets dramatically attenuated the stimulatory effects of CO on β-cell function, whereas interfering PLCβ1 expression had no effects on CO-induced β-cell function enhancement. Our findings showing that CO elevated [Ca2+]i and enhanced GSIS by activating PLC signaling through PLCγ1 and PLCδ1 isoforms in db/db pancreatic β-cells may suggest an important mechanism by which CO promotes β-cell function to prevent hyperglycemia. Our study may also provide new insights into the therapy for type II diabetes and offer a potential target for therapeutic applications of CO.

Keywords: Carbon monoxide; Diabetes; Insulin secretion; Intracellular calcium; Pancreatic β-cells; Phospholipase C.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Calcium / metabolism*
  • Carbon Monoxide / pharmacology*
  • Cell Line
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / genetics
  • Diabetes Mellitus, Experimental / metabolism
  • Diabetes Mellitus, Experimental / pathology
  • Gene Expression Regulation
  • Glucose / metabolism
  • Glucose / pharmacology
  • Hypoglycemic Agents / pharmacology*
  • Insulin / biosynthesis
  • Insulin-Secreting Cells / drug effects*
  • Insulin-Secreting Cells / metabolism
  • Insulin-Secreting Cells / pathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Phospholipase C beta / antagonists & inhibitors
  • Phospholipase C beta / genetics
  • Phospholipase C beta / metabolism
  • Phospholipase C delta / antagonists & inhibitors
  • Phospholipase C delta / genetics*
  • Phospholipase C delta / metabolism
  • Phospholipase C gamma / antagonists & inhibitors
  • Phospholipase C gamma / genetics*
  • Phospholipase C gamma / metabolism
  • Receptors, Leptin / deficiency
  • Receptors, Leptin / genetics
  • Signal Transduction

Substances

  • Hypoglycemic Agents
  • Insulin
  • Receptors, Leptin
  • leptin receptor, mouse
  • Carbon Monoxide
  • Phospholipase C beta
  • Phospholipase C delta
  • Plcb1 protein, mouse
  • Plcd1 protein, mouse
  • Phospholipase C gamma
  • Plcg1 protein, mouse
  • Glucose
  • Calcium